Drug Abuse Institute Seeks PGx Proposals
January 19, 2011
Drug Abuse Institute Seeks PGx Proposals
"The genetics component of the clinical trials will focus on the identification of pharmacogenetic factors that predict patient response to medications and/or between-subject variations in pharmacokinetics, as well as the identification of biomarkers for addiction," NIDA said in a statement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NIDA Wants Education Programs to Use Genetic Data in Addiction Research
June 11, 2012 / GenomeWeb Daily News - Q&A: INMEGEN's Alfredo Hidalgo on Using Genomics to Address Mexico's Most Pressing Health Problems
May 17, 2013 / BioArray News - Aiming at '$12B Opportunity,' Illumina to Expand Sales Presence, Invest in Reproductive Health
May 14, 2013 / BioArray News - Denovo Biomarkers, ALS-ETF Partner on ALS Drug Development Efforts
May 10, 2013 / GenomeWeb Daily News - GenomeWeb Feature: The Rise of Lung Cancer Genetic Testing
May 8, 2013 / Pharmacogenomics Reporter